Skip to Content

Bio-Rad Laboratories Inc Class A

BIO: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$783.00WktlnPmbpwpm

Bio-Rad Delivering Record Profits From Life Science Growth and Sartorius Gains

Business Strategy and Outlook

Bio-Rad develops products and solutions for the life science research and clinical diagnostic markets and has niche market leadership in diagnostic quality controls, antigens, and digital polymerase chain reaction, or PCR, molecular testing. Bio-Rad’s business relies on the razor/razor blade model typically seen in the diagnostic market, and consumable reagents account for approximately 65% of total sales, with these reagents generally sold at a higher margin than their associated equipment and instruments.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BIO so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center